M ost acute ischemic coronary syndromes result from the formation of a platelet-rich thrombus at the site of a ruptured atherosclerotic plaque. 1 Platelet hyperreactivity has been correlated with coronary events and mortality in patients with established coronary artery disease. 2 Platelet aggregation is mediated through the binding of fibrinogen or von Willebrand factor (vWF) to the activated form of the platelet glycoprotein (GP) IIb/IIIa (integrin ␣ IIb ␤ 3 ) receptor. Platelet membrane adhesive receptors are polymorphic, and recent reports of associations between the platelet Pl A2 polymorphism of GP IIIa and ischemic coronary syndromes 3, 4 raise the question as to whether this genetic variation may contribute to platelet hyperreactivity. This is particularly important considering that Ϸ25% of individuals of Northern European ancestry are Pl A2 -positive, with only 2% being homozygous Pl A2 . 5 Standard light transmission ("turbidimetric") platelet aggregometry is designed to detect platelet hypofunction in the evaluation of hemorrhagic conditions. This technique detects only aggregates of several hundred platelets and thus is insensitive to the early stages of platelet aggregation and may be suboptimal in discriminating platelet hyperreactivity. 6 An additional concern regarding the use of platelet-rich plasma (PRP) in turbidimetric aggregometry is the loss of larger, high-density platelets during the centrifugation procedure. Whole-blood platelet aggregation measures electrical impedance caused by platelet thrombus formation on electrodes. However, this technique may suffer from nonreproducibility because of other causes of increased impedance, such as fibrin buildup on the electrodes. We have previously shown that a whole-blood flow cytometric analysis using epitopedependent monoclonal antibodies is an extremely reliable measure of the platelet activation state. 7 Using this assay and several others, we investigated whether the Pl A2 polymorphism might contribute to the heterogeneity observed in platelet GP IIb/IIIa function by testing platelets from 56 normal donors, 16 of whom were Pl A2,A2
. We found that Pl A2 -positive platelets were hyperreactive and demonstrated an altered sensitivity to antiplatelet agents.
Methods

Blood Collection
After the Pl A genotype 5 had been determined, repeat phlebotomy on healthy individuals was performed for functional studies when the donor was in a fasting state and had not taken medications for at least 10 days. The first 2 mL was discarded, then 100 mL of blood was drawn through a 19-gauge needle into 3.2% sodium citrate. Samples were included for functional studies only if there was maximal aggregation to arachidonic acid. In a few cases, not all assays could be performed on all 56 donors, usually because of insufficient blood sample.
Monoclonal Antibodies
Monoclonal antibody F26 is directed against a conformational change in fibrinogen bound to the GP IIb/IIIa complex. 8 Monoclonal antibody LIBS1 is directed against a conformational change in the GP IIb/IIIa complex induced by fibrinogen binding. 9 F26 and LIBS1 were FITC-conjugated as described. 7 Peridinin chlorophyll protein (PerCP)-conjugated CD42a (Becton Dickinson) is a GP IX-specific monoclonal antibody. Phycoerythrin-conjugated monoclonal antibody CD62P (Becton Dickinson) is directed against P-selectin. 10 
Whole-Blood Flow Cytometry
Two-and 3-color whole-blood flow cytometry was performed by a modification of previously described methods, 7 with the operator blinded to the genotype of the donor. Briefly, samples were incubated with CD42a-PerCP 2.5 g/mL, followed by saturating concentrations of antibodies, followed by buffer or agonists. Samples were fixed in 1% formaldehyde, diluted in buffer, and sent at 4°C by overnight delivery to the Center for Platelet Function Studies at the University of Massachusetts Medical Center. All samples were analyzed within 24 hours in an XL flow cytometer (Coulter) as described. 7 In the 2-color assay, color compensation was not required because PerCP does not interfere with FITC. In the 3-color assay, stimulated or unstimulated normal donor samples labeled with test or isotype-matched control antibodies were prepared to establish appropriate color compensation.
Quantification of Platelet Fibrinogen Binding, GP IIb/IIIa, and Platelet Fibrinogen and vWF
PRP was prepared by centrifugation at 120g for 20 minutes. Functional studies were completed within 2.5 hours. We have previously described the FITC-labeled fibrinogen preparation, binding to platelets, and the method of converting fluorescence intensity data to the number of binding sites per cell. 11 The bivalent form (IgG) of monoclonal antibody 7E3, directed against GP IIIa, was used in a radiometric assay at a concentration of 18 g/mL to quantify the number of receptors per platelet as previously described. 12 Fibrinogen and vWF were quantified from washed platelets by an ELISA technique from Accurate Chemical and Scientific Corp and American Diagnostica, Inc.
Platelet Aggregation
PRP was adjusted to 250 000 platelets/L with autologous plateletpoor plasma for use in a BIO-DATA 4-channel platelet aggregometer. One hundred percent aggregation was the optical density obtained with platelet-poor plasma. The sample (450 L) was preincubated at 37°C for 10 minutes. For the inhibition studies, aspirin was added for an additional 10 minutes. Because of variable response to epinephrine, the data for this agonist were used only if Ͼ60% aggregation was obtained with 10 mol/L epinephrine.
IC 50 Determinations
The 50% inhibitory concentration (IC 50 ) of aspirin was modeled for each subject individually. A sigmoid E max model achieved the best fit for nearly all subjects according to an accepted model diagnostic criterion. 13 
Statistics
Data were analyzed by 1-way ANOVA and repeated-measures ANOVA. A Bonferroni-Dunn test was used for post hoc comparisons of individual means. A probability of Ͻ0.05 was considered significant. The IC 50 model parameters were not normally distributed. Accordingly, nonparametric methods were used for comparisons among (Kruskall-Wallis) and between (Mann-Whitney U test) genotype groups to determine statistical significance (2-sided PϽ0.05).
Results
Donor Characteristics
The characteristics of the blood donors are shown in Table 1 according to Pl A genotype. The groups were similarly matched, except that the Pl A2 homozygote group subjects were older than the other groups. There was no difference in platelet counts among the groups.
Subthreshold Platelet Stimulation Studies
Resting platelets that were Pl A2 -positive bound significantly higher levels of CD62P (specific for P-selectin) than did Pl . Error bars indicate SEM. Numbers above bars indicate probability value for differences between 2 means. platelets than to the other genotypes. LIBS1 binding showed a trend toward greater binding to Pl A2 -positive platelets (not shown), and a larger sample size may be necessary to detect a significant difference in LIBS1 binding to resting platelets. In addition, in resting platelets, perhaps the Pl A2 conformation favors fibrinogen and F26 binding without LIBS1 exposure.
When blood was stimulated with low concentrations of ADP, a consistent Pl A2 -dependent increase in binding of CD62P, F26, and LIBS1 was observed (Figure 2 ). Compared with Pl A1,A1 platelets, the homozygous Pl A2,A2 platelets bound significantly more of all 3 antibodies on stimulation with both 0.5 mol/L and 1.0 mol/L ADP. At these same ADP concentrations, significant differences between Pl A1,A2 and Pl A2,A2 platelets were observed for the antibodies detecting GP IIb/IIIa activation: F26 and LIBS1. Similar variations were observed at 0.1 mol/L ADP, although only F26 binding showed significant differences. These differences in binding of activation-dependent antibodies among the 3 genotypes were not due to differences in platelet size as assessed by forward light scatter in the flow cytometer (not shown).
We considered an effect of age on these findings, but the older 8 donors (mean age, 53.6 years) in the Pl A2,A2 group showed no significant differences from the younger 8 donors (mean age, 35.4 years) for any of the antibodies (Table 2 ). In addition, for every experiment in which there was a significant difference between the older half of the Pl A2,A2 group and either Pl A1 -positive group, there was also a significant difference between the younger half of the Pl A2,A2 group and either Pl A1 -positive group (data not shown). From these studies, we conclude that 2 copies of the Pl A2 allele correlated with increased platelet reactivity, as determined by ␣-granule secretion (indicated by surface P-selectin) and the GP IIb/IIIa activation state (indicated by F26 and LIBS1 binding). A single copy of the Pl A2 allele showed a consistent, but not statistically significant, association with increased platelet reactivity.
GP IIb/IIIa Quantification
We used several approaches to assess whether the increased binding of activation-dependent antibodies by Pl A2 genotype was due to a higher absolute number of GP IIb/IIIa receptors. 7E3 is a GP IIb/IIIa-specific monoclonal antibody that can be used to quantify the number of receptors. 12 No difference in the receptor density was observed by Pl A status in nonstimulated platelets (Figure 3 ). When stimulated with 20 mol/L ADP, more GP IIb/IIIa receptors were detected on the Pl A2 -positive platelets than on the Pl A2 -negative platelets. Under the static conditions of these experiments, ADP would not have been expected to cause granule release, 14 consistent with the lack of change observed in the Pl A1,A1 platelets. These results suggested a lower threshold for degranulation in the 
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Pl A2 -positive platelets, consistent with the data in Figure 1 , where a higher P-selectin expression was observed in Pl A2 -positive platelets. Age did not affect the increased 7E3 binding to Pl A2,A2 platelets ( ) compared with unstimulated platelets. We also assessed binding of a GP IIb-specific monoclonal antibody (SZ22) and observed an equivalent binding to platelets of all 3 Pl A genotypes under both resting conditions and stimulation with 20 mol/L TRAP (data not shown). Similar results with TRAP using 2 different antibodies make it unlikely that the difference in 7E3 binding to platelets stimulated with 20 mol/L ADP ( Figure 3 ) was simply due to an altered affinity of 7E3 for the Pl A2 polymorphism. This conclusion is supported further by our findings in stable cell lines overexpressing the Pl A1 or Pl A2 forms of GP IIb/IIIa, which show equivalent binding of 7E3 Fab at concentrations Ͼ1 g/mL (data not shown). We conclude that there is no difference in the total number of surface-accessible GP IIb/IIIa receptors among the 3 Pl A genotypes and that Pl A2 -positive platelets possess a lower threshold for ␣-granule release, with a corresponding increase in GP IIb/IIIa receptor density.
Maximal-Platelet-Stimulation Studies
The binding of exogenously added fibrinogen to maximally stimulated platelets was determined by use of 20 mol/L ADP. Under these conditions, no significant differences were observed among the 3 genotypes (Table 3) . Similarly, maximal stimulation with 20 mol/L ADP and 20 mol/L TRAP in platelet aggregometry studies negated any subthreshold difference (Table 3) . Indeed, the only difference observed in aggregation studies was with 0.4 mol/L epinephrine, in which Pl A2,A2 platelets showed greater aggregation than Pl A1 -positive platelets. Finally, there were no significant differences among the Pl A1,A1 and Pl A1,A2 genotypes in intracellular fibrinogen or vWF ( Table 3) .
Influence of Pl A Status on Aspirin and Abciximab Inhibition of ADP-Induced Platelet Aggregation
Aspirin is a mainstay in the treatment of coronary artery disease, and it inhibits epinephrine-induced platelet aggregation. We observed significant differences in platelet inhibition among Pl A genotypes at 2.5 and 5 mol/L aspirin ( Figure  4A ), concentrations that are typically obtained in vivo. 15 As we have previously reported, 16 the Pl A1,A2 platelets were the most sensitive to aspirin. Interestingly, Pl A2,A2 platelets, which were not studied previously, were less sensitive than Pl A1,A2 platelets and only slightly less sensitive than Pl A1,A1 platelets. Abciximab is a monovalent chimeric Fab fragment of 7E3 that blocks ligand binding to GP IIb/IIIa and has been beneficial in a number of coronary ischemic syndromes. 17 As with aspirin, several concentrations of abciximab, within the range of concentrations that partially or completely block platelet aggregation, 18 caused significant differences among genotypes in inhibiting aggregation ( Figure 4B ). There were statistically significant differences in the aspirin IC 50 (Table  4) among genotypes (Pϭ0.024), with Pl A2,A2 having the highest value relative to the other genotypes. Individual Figure 2 ). †Differences in mean age by the unpaired t test; other comparisons by repeated-measures ANOVA. 
Discussion
Our studies demonstrate that Pl A2 -positive platelets, compared with Pl A1,A1 platelets, have a lower threshold for platelet activation, ␣-granule release, GP IIb/IIIa activation, and fibrinogen binding. This "hyperreactive" state suggests that in vivo, Pl A2 -positive platelets may exert a greater thrombotic tendency than Pl A1,A1 platelets. We also observed a greater sensitivity to therapeutic concentrations of aspirin and abciximab in Pl A1,A2 platelets. This differential sensitivity to antiplatelet agents may have potential clinical implications whereby specific antiplatelet therapy may best be tailored according to a patient's Pl A genotype. On the basis of the findings in this mechanistic study, further studies are warranted to examine the in vivo effects of antiplatelet agents according to inherited variations in platelet adhesive receptors.
A panel of monoclonal antibodies reporting the activation state of platelets and GP IIb/IIIa consistently demonstrated a higher degree of activation in Pl A2 -positive platelets. Pl A2 -positive platelets had a lower threshold for ␣-granule release, as shown by increased CD62P binding (Figures 1 and 2 ) and 7E3 binding observed with 20 mol/L ADP (Figure 3) . Presumably, the increased fibrinogen occupancy of Pl A2 -positive GP IIb/IIIa receptors in the resting state or on weak agonist stimulation results in greater outside-in signaling and subsequent degranulation and P-selectin expression. The F26 antibody displayed an increased binding to ADP-stimulated Pl A2 -positive platelets and showed greater sensitivity than LIBS1 at detecting these activation differences. We observed both an increased LIBS1 binding in resting Pl A2 -positive platelets and a consistently greater activation of Pl A1,A2 platelets compared with Pl A1,A1 platelets, but statistical significance was not reached in either case. A larger sample size may be necessary to detect true differences. Our data were consistent with an age independence of the Pl A2 effect, but because of the relatively small numbers of subjects compared when the Pl A2,A2 group was divided in half (Table 2) , further investigation in a larger population is warranted. Nevertheless, our findings are strongly supported by Feng et al, 19 who showed that age did not affect Pl A2 -induced platelet hyperreactivity among 1422 subjects.
Light transmission platelet aggregometry continues to be used as the "gold standard" of platelet function assays. However, the typical concentrations of agonists used in platelet aggregation studies may not be optimal for detecting platelet hyperreactivity. The only significant difference in aggregation by Pl A status in our study was with low-dose epinephrine as an agonist, a finding consistent with the low-dose ADP data in our whole-blood assay ( Figure 2 ) and observations that less epinephrine is required for aggregating Pl A2 -positive than Pl A2 -negative platelets. 19 Platelets display an "all-or-none" activation response, 20 which may explain why strong agonists were able to bypass or overcome the Pl A2 -dependent difference seen with weak agonists (Table 3 ). In addition, because thrombogenesis under high shear rates typically proceeds via GP IIb/IIIa-ligand interactions after platelets have adhered to the subendothelium via vWF, 21 differences in the activation state of GP IIb/IIIa or the threshold for granule release may not be apparent in the aggregometer, where low shear forces and repetitive interactions may provide sufficient time for bonds to form. Interestingly, heterozygous platelets showed a greater sensitivity to 2 platelet inhibitors: aspirin and abciximab. It is not clear why the Pl A2,A2 subjects responded to the inhibitors in a manner more like the Pl A1,A1 group. Receptor clustering augments GP IIb/IIIa-mediated signaling, 22 and perhaps such clustering may be inhibited in heterozygous platelets such that they are more susceptible to inhibition by aspirin or abciximab. For example, in studies with GP IIb/IIIa-expressing cell lines, we have found increased adhesion in Pl A2 -expressing cells compared with Pl A1 -expressing cells that is mediated through differences in outside-in signaling, 23 and perhaps the combination of both allele products dominantly inhibits this component of receptor-mediated cell activation. The concentrations of both aspirin and abciximab used in these experiments were within the therapeutic range achieved in vivo. 15, 18 Thus, the significant differences in inhibition observed at 2.5 and 5.0 mol/L aspirin and 1.25 and 1.5 g/mL abciximab may affect either beneficial (antithrombotic) or adverse (hemorrhagic) in vivo effects. It will be interesting to see whether other structurally different platelet or GP IIb/IIIa antagonists display variable inhibitory activity by Pl A genotype. Nevertheless, our data should be interpreted cautiously until they are confirmed in a larger series. In the meantime, future clinical epidemiology studies of platelet genetic variations and cardiovascular disease would be wise to consider possible treatment effects.
It is difficult to extrapolate these Pl A -dependent differences in platelet function to the clinical condition, because platelet behavior in young, healthy donors is likely to be quite different from that in older patients with coronary artery disease, in which numerous other effects (cardiovascular medications, hormonal alterations, serum lipids, tobacco use, injured vessel wall, etc) affect platelet physiology. But because GP IIb/IIIa is the most abundant receptor on human blood platelets (Ϸ80 000 copies per platelet) and plays a central role in formation of a platelet thrombus, even a subtle functional alteration could have profound effects over the lifetime of a patient.
